

Megan T. Kirchner, BA, CCRP

Dawes Fretzin Clinical Research Group, LLC

7910 North Shadeland Avenue
Indianapolis, Indiana 46250
Phone (317) 516-5030 Ext. 105
Fax (317) 516-5031
Email: mkirchner@ecomunity.com

Dawes Fretzin Dermatology Group, LLC

7910 North Shadeland Avenue
Indianapolis, Indiana 46250
Phone (317) 516-5030 Ext. 105
Fax (317) 516-5031

Education

Indiana University, (Bloomington, IN)
Bachelor of General Education, 2010

Professional Experience

Dawes Fretzin Clinical Research Group, LLC (Indianapolis, IN)
Study Coordinator, March 2023-Present

Dawes Fretzin Dermatology Group, LLC (Indianapolis, IN)
Research Assistant, March 2023-Present

Indiana University School of Medicine (Indianapolis, IN)
Research Coordinator, January 2019-March 2022

Indiana University School of Medicine (Indianapolis, IN)
Clinical Research Specialist, July 2017-January 2019

ForeFront Dermatology (Carmel, IN)
Clinical Research Coordinator, February 2013- July 2017

Megan Kirchner
16 JUN 2026

License/Certifications

Certified Clinical Research Professional – SOCRA
CITI Certification
IATA Certification
BLS Certification

Publications

Beam, CA, Beli E., Wasserfall CH, Woerner SE, **Legge (Kirchner) MT**, Evans-Molina, C., McGrail KM, Silk R., Grant MB, Atkinson MA, DiMeglio LA. Peripheral Immune Circadian Variation, Synchronization and Possible Dysrhythmia in Established Type 1 Diabetes. *Diabetologia*. 2021; 64(8): 1822-183

Megan T. Kirchner, BA, CCRP

Clinical Studies conducted at Dawes Fretzin Clinical Research Group, LLC

Sponsor	Protocol	Indication	Role	Phase	Date of COV
UPENN	Acne	Acne	Sub-I	4	16-Apr-25
Sanofi	VBE00001	Acne	Sub-I	1/2	24-Feb-26
Arena	APD334-205	Alopecia Areata	Sub-I	2	30-Aug-23
Pfizer	B7981031	Alopecia Areata	Sub-I	1	17-Oct-23
Inmagene	IMG-007-002	Alopecia Areata	Sub-I	1b/2a	28-Jun-24
Pfizer	B7981032	Alopecia Areata	Sub-I	3	01-Aug-24
Aslan	ASLAN003-004	Alopecia Areata	Sub-I	2a	12-Aug-24
Sanofi	DRI18180	Alopecia Areata	Sub-I	2	10-Feb-25
Lilly	I4V-MC-JAIR	Alopecia Areata	Sub-I	3	13-Mar-25
Adelphi	AG9909	Alopecia Areata	Sub-I	OBS	15-Apr-26
Concert	CP543.5001	Alopecia Areata	Sub-I	3	28-Apr-26
Abbvie	M24-725	Alopecia Areata	Sub-I	3	ONGOING
CorEvitas	AA-565	Alopecia Areata	Sub-I	OBS	ONGOING
Pfizer	B7981027	Alopecia Areata	Sub-I	3	ONGOING
Pfizer	B7981028	Alopecia Areata	Sub-I	3	ONGOING
Pfizer	B7981094	Alopecia Areata	Sub-I	3	ONGOING
Pfizer	B7981110	Alopecia Areata	Sub-I	3	ONGOING
DrenBio	DR-01-AIM-001	Alopecia Areata	Sub-I	1b	ONGOING
HCW Biologics	HCWALO101	Alopecia Areata	Sub-I	1b	ONGOING
Lilly	I4V-MC-JAIO	Alopecia Areata	Sub-I	3	ONGOING
Sun Pharma	CP543.3101	Alopecia Areata	Sub-I	3	ONGOING
Pelage	PP405-2001	Androgenetic Alopecia	Sub-I	2a	24-Nov-25
Pelage	PP405-2002	Androgenetic Alopecia	Sub-I	2/3	ONGOING
Veradermics	250-13951-302	Androgenetic Alopecia	Sub-I	3	ONGOING
Veradermics	250-13951-306	Androgenetic Alopecia	Sub-I	3	ONGOING
DermTech	20-03	Atopic Dermatitis	Sub-I	4	24-Oct-23
Acrotech	MEDI-MM36-301	Atopic Dermatitis	Sub-I	3	20-Nov-23
Evidera	EVA-25835	Atopic Dermatitis	Sub-I	OBS	15-Dec-23
Galderma	RD.06.SPR.118380	Atopic Dermatitis	Sub-I	2	21-Dec-23
Aslan	ASLAN004-003	Atopic Dermatitis	Sub-I	2b	04-Jan-24
Aclaris	ATI-1777-AD-202	Atopic Dermatitis	Sub-I	2b	06-Feb-24
Alumis	ESK-001-007	Atopic Dermatitis	Sub-I	2	13-Feb-24
TrialSpark	ASN008-201	Atopic Dermatitis	Sub-I	2	14-Feb-24
Cara	CR845-310501	Atopic Dermatitis	Sub-I	3	07-Mar-24
Kymab	KY1005-CT05	Atopic Dermatitis	Sub-I	2b	02-May-24
Rapt	RPT193-02	Atopic Dermatitis	Sub-I	2	07-Jun-24
Incyte	INCB18424-305	Atopic Dermatitis	Sub-I	3	26-Jun-24
Acrotech	MEDI-MM36-302	Atopic Dermatitis	Sub-I	3	16-Jul-24
Biosion	BSI-045B-002	Atopic Dermatitis	Sub-I	2a	18-Jul-24
Abbvie	M16-049	Atopic Dermatitis	Sub-I	2b	29-Oct-24
Abbvie	M23-696	Atopic Dermatitis	Sub-I	3b/4	29-Oct-24
Taro	RXLC-2118	Atopic Dermatitis	Sub-I	4	04-Dec-24

Megan T. Kirchner, BA, CCRP

Sponsor	Protocol	Indication	Role	Phase	Date of COV
Incyte	INCB18424-902	Atopic Dermatitis	Sub-I	4	05-Feb-25
Pfizer	B7451015	Atopic Dermatitis	Sub-I	3	25-Mar-25
Lilly	J2T-MC-KGBO	Atopic Dermatitis	Sub-I	3b	01-Apr-25
Lilly	J2T-MC-KGBP	Atopic Dermatitis	Sub-I	3b	02-Apr-25
Dermira	DRM06-AD07	Atopic Dermatitis	Sub-I	3	09-Apr-25
Amgen	20210144	Atopic Dermatitis	Sub-I	3	29-Apr-25
Galderma	RD.06.SPR.118126	Atopic Dermatitis	Sub-I	2	11-Jun-25
Abbvie	M24-601	Atopic Dermatitis	Sub-I	3b/4	12-Jun-25
LEO	LP0145-2240	Atopic Dermatitis	Sub-I	2b	25-Jun-25
Apollo	AP43CP03	Atopic Dermatitis	Sub-I	2	04-Nov-25
CastleBio Science	CBI_2021_ISD_DeVal_001	Atopic Dermatitis	Sub-I	4	02-Dec-25
Galderma	RD.06.SPR.118163	Atopic Dermatitis	Sub-I	3	20-Jan-26
Sanofi	EFC17561	Atopic Dermatitis	Sub-I	3	03-Feb-26
Abbvie	M16-045	Atopic Dermatitis	Sub-I	3	04-Feb-26
Amgen	20210145	Atopic Dermatitis	Sub-I	3	26-Feb-26
TARGET-DERM	TARGET-DERM	Atopic Dermatitis	Sub-I	4	06-Apr-26
Janssen	95475939ADM2001	Atopic Dermatitis	Sub-I	2b	12-May-26
Roche	CS45943	Atopic Dermatitis	Sub-I	2	N/A
Abbvie	M16-047	Atopic Dermatitis	Sub-I	3	ONGOING
Abbvie	M17-380	Atopic Dermatitis	Sub-I	3	ONGOING
Aclaris	ATI-045-AD-201	Atopic Dermatitis	Sub-I	2b	ONGOING
Amgen	20210146	Atopic Dermatitis	Sub-I	3	ONGOING
Anacor	AN2728-AD-301-302-POST01	Atopic Dermatitis	Sub-I	OBS	ONGOING
Apogee	APG777-301	Atopic Dermatitis	Sub-I	3	ONGOING
Apollo	AP43CP04	Atopic Dermatitis	Sub-I	2b	ONGOING
CorEvitas	AD-550	Atopic Dermatitis	Sub-I	4	ONGOING
Corrona	Corrona-AD-550	Atopic Dermatitis	Sub-I	4	ONGOING
Galderma	SPR207806	Atopic Dermatitis	Sub-I	OBS	ONGOING
Janssen	95597528ADM2001	Atopic Dermatitis	Sub-I	2b	ONGOING
Lilly	J2T-MC-KGCE	Atopic Dermatitis	Sub-I	4	ONGOING
Pfizer	B7451023	Atopic Dermatitis	Sub-I	3	ONGOING
Pfizer	B7451031	Atopic Dermatitis	Sub-I	3	ONGOING
Pfizer	C4531002	Atopic Dermatitis	Sub-I	2	ONGOING
Pfizer	C4531005	Atopic Dermatitis	Sub-I	3	ONGOING
Roche	CS45570	Atopic Dermatitis	Sub-I	2	ONGOING
Sanofi	EFC17599	Atopic Dermatitis	Sub-I	3	ONGOING
Sanofi	EFC17600	Atopic Dermatitis	Sub-I	3	ONGOING
Sanofi	LTS17367	Atopic Dermatitis	Sub-I	2/3	ONGOING
Attovia	ATTO-3712-101	Atopic Dermatitis	Sub-I	1	ONGOING
Enveda	ENV-294-202	Atopic Dermatitis	Sub-I	2b	ONGOING
Lilly	J2T-MC-B002	Atopic Dermatitis	Sub-I	4	ONGOING
Organon	OG0505-3104	Atopic Dermatitis	Sub-I	3	ONGOING
Triveni Bio	TRIV-509-101	Atopic Dermatitis	Sub-I	2a	ONGOING
Triveni Bio	TRIV-573-101	Atopic Dermatitis	Sub-I	2	ONGOING

Megan T. Kirchner, BA, CCRP

Sponsor	Protocol	Indication	Role	Phase	Date of COV
Evommune	EVO756-CIU001	Chronic Inducible Urticaria	Sub-I	2a	20-Jun-25
Celldex	CDX0159-07	Chronic Inducible Urticaria	Sub-I	2	25-Nov-25
Sanofi	EFC16973	Chronic Pruritus of Unknown Origin	Sub-I	3	13-Nov-24
Galderma	SPR207913	Chronic Pruritus of Unknown Origin	Sub-I	2	ONGOING
Novartis	CLOU064R12301	Chronic Pruritus of Unknown Origin	Sub-I	3	ONGOING
Celldex	CDX0159-06	Chronic Spontaneous Urticaria	Sub-I	2	07-Nov-23
Escient	EP-262-201	Chronic Spontaneous Urticaria	Sub-I	2	26-Mar-25
InflaRX	INF904-P2.1	Chronic Spontaneous Urticaria	Sub-I	2a	04-Dec-25
Jasper Therapeutics	JSP-CP-011	Chronic Spontaneous Urticaria	Sub-I	2a	ONGOING
Jasper Therapeutics	JSP-CP-014	Chronic Spontaneous Urticaria	Sub-I	2	ONGOING
Novartis	CLOU064AUS04	Chronic Spontaneous Urticaria	Sub-I	OBS	ONGOING
Blueprint Medicines	BLU-808-1201	Chronic Spontaneous Urticaria	Sub-I	2	ONGOING
Celldex	CDX0159-12	Chronic Spontaneous Urticaria	Sub-I	3	ONGOING
Celldex	CDX0159-17	Chronic Spontaneous Urticaria	Sub-I	3b	ONGOING
Merck	MS200569-0003	Cutaneous Lupus Erythematosus	Sub-I	2	16-Jan-25
Merck	MS200569-0048	Cutaneous Lupus Erythematosus	Sub-I	1	28-Jan-26
Gilead	GS-US-497-6486	Cutaneous Lupus Erythematosus	Sub-I	2a	19-May-26
Merck	MS504908_0008	Cutaneous Lupus Erythematosus	Sub-I	3	ONGOING
Ventus	VENT-03-201	Cutaneous Lupus Erythematosus	Sub-I	2a	ONGOING
Horizon	HZNP-DAX-202	Cutaneous Lupus Erythematosus	Sub-I	2	21-Nov-25
Nflection	NFX-179-NFI-202	Cutaneous Neurofibroma	Sub-I	2	16-Oct-23
Regeneron	R2810-ONC-2251	Cutaneous Squamous Cell Carcinoma	Sub-I	3	28-May-26
CastleBio Science	CBI_2019_cSCC_PVS_001	Cutaneous Squamous Cell Carcinoma	Sub-I	4	ONGOING
Soligenix	HPN-CTCL-03-EUR	Cutaneous T-Cell Lymphoma	Sub-I	3	ONGOING
Lilly	J2T-MC-KGCD	Hand/Foot Dermatitis	Sub-I	3b	ONGOING
Acelyrin	21102	Hidradenitis Suppurativa	Sub-I	2	16-Apr-24
Acelyrin	22107	Hidradenitis Suppurativa	Sub-I	3	26-Feb-25
Adelphi	AB6762B	Hidradenitis Suppurativa	Sub-I	OBS	01-Mar-25
Boehringer Ingelheim	1368-0098	Hidradenitis Suppurativa	Sub-I	2b/3	31-Jul-25
Novartis	CAIN457M2301E1	Hidradenitis Suppurativa	Sub-I	3	26-Aug-25
Incyte	INCB54707-302	Hidradenitis Suppurativa	Sub-I	3	23-Jan-26
Incyte	INCB54707-301	Hidradenitis Suppurativa	Sub-I	3	17-Feb-26
Sanofi	ACT17841	Hidradenitis Suppurativa	Sub-I	2	19-Feb-26
Moonlake	M1095-HS-304	Hidradenitis Suppurativa	Sub-I	3	21-May-26
Abbvie	M20-262	Hidradenitis Suppurativa	Sub-I	2	ONGOING
Abbvie	M20-465	Hidradenitis Suppurativa	Sub-I	3	ONGOING
Abbvie	M23-698	Hidradenitis Suppurativa	Sub-I	3	ONGOING
Lilly	I7P-MC-DSAF	Hidradenitis Suppurativa	Sub-I	2b	ONGOING
Merck	MK7240-012	Hidradenitis Suppurativa	Sub-I	2b	ONGOING
Pfizer	B7981119	Hidradenitis Suppurativa	Sub-I	2	ONGOING
Incyte	INCB054707-801	Hidradenitis Suppurativa	Sub-I	3b	ONGOING
Incyte	INCB54707-312	Hidradenitis Suppurativa	Sub-I	3	ONGOING
Incyte	INCB54707-312	Hidradenitis Suppurativa	Sub-I	3	ONGOING
Moonlake	M1095-HS-301	Hidradenitis Suppurativa	Sub-I	3	ONGOING

Megan T. Kirchner, BA, CCRP

Sponsor	Protocol	Indication	Role	Phase	Date of COV
Novartis	CCFZ533H12201BC	Hidradenitis Suppurativa	Sub-I	2	ONGOING
Novartis	CLOU064J12301	Hidradenitis Suppurativa	Sub-I	3	ONGOING
Timber	TMB01-301/MUST	Lamellar Ichthyosis	Sub-I	3	03-Dec-24
Privant	PVT-2201-304	Lichen Planopilaris	Sub-I	2/3	ONGOING
Incyte	INCB18424-216	Lichen Planus	Sub-I	2	25-Apr-24
Novartis	CGIA362C12201	Lichen Planus	Sub-I	2	ONGOING
Evidera	EVA-36509-02	Lower Abdominal Fat	Sub-I	OBS	18-Jul-24
Evidera	EVA-36509-04	Lower Abdominal Fat	Sub-I	OBS	23-Jan-25
Evidera	EVA-36509-08	Lower Abdominal Fat	Sub-I	OBS	18-Sep-25
Evidera	146323-01	Lower Abdominal Fat	Sub-I	OBS	01-Nov-25
Evidera	152364-01	Lower Abdominal Fat	Sub-I	OBS	01-Jun-26
DermTech	17-06	Multi-Indication	Sub-I	4	17-Jun-24
Lilly	l1F-MC-B018	Nail Psoriasis	Sub-I	OBS	29-Jan-25
Quoin	CL-QRX003-001	Netherton Syndrome	Sub-I	2	08-Apr-26
BioCryst	BCX17725-101	Netherton Syndrome	Sub-I	1	ONGOING
Quoin	CL-QRX003-002	Netherton Syndrome	Sub-I	2	ONGOING
Quoin	CL-QRX003-004	Netherton Syndrome	Sub-I	3	ONGOING
Quoin	CL-QRX003-005	Netherton Syndrome	Sub-I	3	ONGOING
Quoin	CL-QRX003-006	Netherton Syndrome	Sub-I	3	ONGOING
DermTech	21-02	Normal Skin	Sub-I	4	29-Jan-24
Mindera	MND-24-MK-02	Normal Skin	Sub-I	1	30-Sep-25
Evidera	EVA-37056-00	Notalgia Parasthetica	Sub-I	OBS	24-Apr-24
Cara	CR845-310601	Notalgia Parasthetica	Sub-I	2-3	02-Jul-24
Clexio	CLE400-NP-201	Notalgia Parasthetica	Sub-I	2	24-Jan-25
BMS	IM011-1112	Palmoplantar Psoriasis	Sub-I	4	02-Jul-25
Incyte	INCB18424-110	Prurigo Nodularis	Sub-I	1	09-May-25
Galderma	SPR207807	Prurigo Nodularis	Sub-I	OBS	ONGOING
InnoCare	ICP-CL-00609	Prurigo Nodularis	Sub-I	2	ONGOING
Sanofi	OBS17721	Prurigo Nodularis	Sub-I	4	ONGOING
Biocon	BM12H-PSO-03-G-02	Psoriasis	Sub-I	3	11-Jan-24
Ventyx	VTX958-201	Psoriasis	Sub-I	2	13-Feb-24
Janssen	77242113PSO3001	Psoriasis	Sub-I	3	19-Mar-24
DICE Therapeutics	DCE806201	Psoriasis	Sub-I	2	28-Mar-24
Mindera	MND-21-MKPs-02	Psoriasis	Sub-I	4	28-May-24
LITE	PCS-1608-35830	Psoriasis	Sub-I	2/3	05-Jul-24
UCB	PS0020	Psoriasis	Sub-I	2	17-Jul-24
Sanofi	DRI17849	Psoriasis	Sub-I	2	03-Dec-24
Janssen	77242113PSO3003	Psoriasis	Sub-I	3	14-Jan-25
Janssen	77242113PSO3002	Psoriasis	Sub-I	3	20-Feb-25
BMS	IM011-075	Psoriasis	Sub-I	3b	06-May-25
Janssen	CNT01959PSO3018	Psoriasis	Sub-I	3b	10-Sep-25
Takeda	TAK279-3001	Psoriasis	Sub-I	3	20-Jan-26
Alumis	ESK-001-016	Psoriasis	Sub-I	3	17-Feb-26
Dermavant	DMVT-505-3004	Psoriasis	Sub-I	3	11-Mar-26

Megan T. Kirchner, BA, CCRP

Sponsor	Protocol	Indication	Role	Phase	Date of COV
Celgene	CC-10004-PPSO-004	Psoriasis	Sub-I	3b	24-Mar-26
Abbvie	M24-541	Psoriasis	Sub-I	4	02-Jun-26
Takeda	TAK-279-PsO-3004	Psoriasis	Sub-I	3	02-Jun-26
Amgen	20200196	Psoriasis	Sub-I	3	ONGOING
BMS	IM011-1128	Psoriasis	Sub-I	3	ONGOING
BMS	IM011-1130	Psoriasis	Sub-I	3b/4	ONGOING
CorEvitas	CorEvitas-PSO-505	Psoriasis	Sub-I	OBS	ONGOING
Corrona	Corrona-PSO-550	Psoriasis	Sub-I	4	ONGOING
Lilly	I1F-MC-RHDC	Psoriasis	Sub-I	3b	ONGOING
Lilly	I1F-MC-RHDD	Psoriasis	Sub-I	3b	ONGOING
UCB	PS0021	Psoriasis	Sub-I	3	ONGOING
UPENN	CP3	Psoriasis	Sub-I	4	ONGOING
Alumis	ESK-001-018	Psoriasis	Sub-I	3	ONGOING
InventisBio	D2570-207	Psoriasis	Sub-I	2	ONGOING
Takeda	TAK279-3003	Psoriasis	Sub-I	3	ONGOING
Novartis	CAIN457A02001B	Psoriatic Arthritis	Sub-I	4	23-Jan-25
Boehringer Ingelheim	1368-0140	Pyoderma Gangrenosum	Sub-I	3	ONGOING
Evidera	EVA-20371-01	Scalp Psoriasis	Sub-I	OBS	11-Jan-24
BMS	IM011-220	Scalp Psoriasis	Sub-I	3b/4	19-Nov-24
Evidera	EVA-44850	Skin Tone Assessment	Sub-I	OBS	ONGOING
Merck	MK-6194-007	Vitiligo	Sub-I	2a	20-May-25
VYNE	VY2024-02	Vitiligo	Sub-I	2b	30-Jul-25
Pfizer	B7981080	Vitiligo	Sub-I	3	10-Sep-25
Pfizer	B7981040	Vitiligo	Sub-I	3	05-Mar-26
Abbvie	M19-044	Vitiligo	Sub-I	3	ONGOING
Abbvie	M25-264	Vitiligo	Sub-I	3	ONGOING
Lilly	J5D-MC-FPAD	Vitiligo	Sub-I	2	ONGOING
Pfizer	B7981041	Vitiligo	Sub-I	3	ONGOING
Novartis	CGIA362B12201	Vitiligo	Sub-I	2	ONGOING